BPC July 14 update

​Glaukos GKOS shares fall on CMS fee schedule -21%; CohBar CWBR data delay -18%

Price and Volume Movers

CohBar, Inc. (NASDAQ:CWBR) announced the release of data from its Phase 1a/1b trial of CB4211 for the potential treatment of nonalcoholic steatohepatitis and obesity has been delayed. Initially slated for release during early-July 2021, the company now expects data to be available sometime prior to Labor Day (September 6, 2021). Shares fell 18% to $1.13.

Glaukos Corporation (NASDAQ:GKOS) shares fell 21% to $57.82 following the release by the Centers for Medicare and Medicaid Services (CMS) of their fee schedule for 2022, well below expectations, with their CEO noting that the company is extremely disappointed with the proposed fees. Analysts from both William Blair and Oppenheimer downgraded their rating of the stock from Outperform to Perform.

INmune Bio, Inc. (NASDAQ:INMB) announced a registered direct offering of 1,818,182 shares of its common stock at a price of $22.00 per share for gross proceeds of approximately $40 million. Shares fell 14% to $22.96.

Imara Inc. (Nasdaq: IMRA) shares fell 17% to $5.90 following the pricing late-Tuesday of its public offering of shares of its common stock at a price of $6.00 per share, for gross proceeds of $50 million.

Immunic, Inc. (NASDAQ:IMUX) shares are trading down 11% after hours following its announcement that it intends to offer and sell shares of its common stock in an underwritten public offering.

IMV Inc. (NASDAQ:IMV, TSX:IMV) shares have dropped 13% after hours to $1.82 after it announced it has filed a Preliminary Prospectus Supplement for a proposed public offering of common shares and warrants.

-

Other major price movers (stocks priced > $1.00, volume > 50k listed on NASDAQ/NYSE):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume:

ADVANCERS:

Virpax Pharmaceuticals, Inc. (VRPX): $7.38; +31%.

AcelRx Pharmaceuticals, Inc. (ACRX): $1.51; +24%.

Tempest Therapeutics Inc. (TPST): $22.52; +9%.

PLx Pharma Inc. (PLXP): $17.07; +8%.

Ayala Pharmaceuticals, Inc. (AYLA): $11.69; +7%.

DECLINERS:

Unicycive Therapeutics, Inc. (UNCY): $3.80; -35%.

Prometheus Biosciences, Inc. (RXDX): $20.89; -21%.

Clene Inc. (CLNN): $10.89; -20%.

Recursion Pharmaceuticals, Inc. (RXRX): $33.31; -19%.

TransCode Therapeutics, Inc. (RNAZ): $3.83; -16%.

Pipeline updates below:

Pipeline Database Updates

Drug Price Stage Catalyst Market Cap

BCTX – BriaCell Therapeutics Corp.
Bria-IMT with retifanlimab and epacadostat
Breast cancer

$5.08
-0.41  -7%
Phase 1/2 Phase 1/2 trial open for enrollment - July 14, 2021.
$77.3 million

CWBR – CohBar Inc.
CB4211
Nonalcoholic Fatty Liver Disease / Obesity / Nonalcoholic steatohepatitis

$1.12
-0.01  -1%
Phase 1b Phase 1b top-line data due prior to Labor Day (September 6, 2021).
$69.2 million

GLPG – Galapagos NV
GLPG3970 (CALOSOMA)
Psoriasis

$60.54
0.00  0%
Phase 1b Phase 1b data released July 14, 2021. 4/13 patients exhibited a response at Week 6.
$4 billion

GLPG – Galapagos NV
GLPG3970 (LADYBUG)
Rheumatoid Arthritis

$60.54
0.00  0%
Phase 2a Phase 2a data released July 14, 2021 - showed no differentiation from placebo.
$4 billion

GLPG – Galapagos NV
GLPG3970 (SEA TURTLE)
Ulcerative Colitis

$60.54
0.00  0%
Phase 2 Phase 2 data released July 14, 2021. No differentiation from placebo.
$4 billion